Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult Subjects

Clinical trial NCT03863587 · TERMINATED

Trial details

NCT number: NCT03863587
Sponsor: Shanghai Henlius Biotech
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Healthy Male Volunteers

Start date: 2019-06-06
Primary completion: 2019-09-24
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.